Medicamen Organics Ltd. Share Price

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) Cohance Lifesciences has informed that the Company has received an order from the Telangana Pollution Control Board (‘TGPCB’) directing closure of operations at the Company’s manufacturing site at Suryapet, Telangana. The closure order has been issued following an industrial accident that occurred during the manufacturing process, resulting in exposure to one employee on duty at the facility. The employee was immediately provided emergency medical assistance and was subsequently shifted to a specialized hospital in Hyderabad for advanced treatment. Despite receiving the best possible medical care and sustained efforts by the attending medical teams, the employee unfortunately succumbed to his injuries. The Company has immediately initiated appropriate corrective and preventive measures to address the observations stated in the directions issued by TGPCB and expects to promptly submit the requisite representations and compliances to TBPCB, for seeking cancellation of the closure directions at the earliest and allowing the site to resume operations. The Company will keep the Stock Exchanges informed of any material developments in this regard. The details required under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated 30 January 2026 are enclosed as Annexure I. The disclosure containing details of the communication received from TGPCB, as required under Regulation 30(13) of the SEBI Listing Regulations read with the Industry Standards prescribed by the Industry Standards Forum (ISF), is enclosed as Annexure II.

Fredun Pharmaceuticals has informed that it enclosed press release titled ‘FREDUN PHARMACEUTICALS ON A GROWTH OVERDRIVE: NET PROFIT SOARS 94%, EBITDA ROCKETS 92% AND REVENUE SURGES 87% IN H1 FY27’. 

The above information is a part of company’s filings submitted to BSE. 

The revenue for the September 2026 quarter is pegged at Rs. 190.09 millions against Rs. 190.09 millions recorded during the year-ago period.Net profit of the cmpany stood at Rs. 6.73 millions for the quarter ended September 2026 a decline of -59.06% from Rs. 16.44 millions  in the same quarter last year.The Operating Profit of the company witnessed a decrease to 18.15 millions from 29.19 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	190.09	190.09	0.00	349.72	371.44	-5.85	759.37	751.01	1.11
Other Income	3.78	7.91	-52.21	4.30	9.72	-55.76	19.55	10.69	82.88
PBIDT	18.15	29.19	-37.82	30.59	54.54	-43.91	109.96	80.85	36.00
Interest	1.62	1.32	22.73	2.85	2.77	2.89	5.45	5.48	-0.55
PBDT	16.53	27.87	-40.69	27.74	51.77	-46.42	100.56	75.37	33.42
Depreciation	7.37	8.63	-14.60	14.66	17.06	-14.07	34.20	28.76	18.92
PBT	9.16	19.24	-52.39	13.08	34.71	-62.32	66.36	46.61	42.37
TAX	2.43	2.80	-13.21	3.37	8.60	-60.81	18.03	15.16	18.93
Deferred Tax	0.13	-2.90	-104.48	-0.23	-1.90	-87.89	1.42	1.68	-15.48
PAT	6.73	16.44	-59.06	9.71	26.11	-62.81	48.33	31.45	53.67
Equity	12.00	12.00	0.00	12.00	12.00	0.00	12.00	12.00	0.00
PBIDTM(%)	9.55	15.36	-37.82	8.75	14.68	-40.43	14.48	10.77	34.51

An increase of about 84.21% to Rs. 2676.35 millions in the topline was observed for the quarter ended September 2026. The topline stood at Rs. 1452.91 millions during the similar quarter previous year.The Profit  for the quarter ended September 2026 of  Rs. 188.26  millions  grew by 93.46% from Rs. 97.31 millions.Operating profit for the quarter ended September 2026 rose to 426.02 millions as compared to 223.34 millions of corresponding quarter ended September 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	2676.35	1452.91	84.21	4958.83	2651.46	87.02	6391.21	4562.68	40.08
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBIDT	426.02	223.34	90.75	753.78	393.25	91.68	947.94	550.97	72.05
Interest	87.76	77.31	13.52	173.94	142.63	21.95	392.98	223.77	75.62
PBDT	338.26	146.03	131.64	579.84	250.62	131.36	554.96	327.20	69.61
Depreciation	39.23	15.98	145.49	74.94	30.17	148.39	79.14	44.49	77.88
PBT	299.03	130.05	129.93	504.90	220.45	129.03	475.82	282.71	68.31
TAX	110.77	32.74	238.33	184.97	55.49	233.34	143.75	74.63	92.62
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	188.26	97.31	93.46	319.93	164.96	93.94	332.07	208.08	59.59
Equity	169.00	141.65	19.31	169.00	141.65	19.31	54.73	47.22	15.90
PBIDTM(%)	15.92	15.37	3.55	15.20	14.83	2.49	14.83	12.08	22.83

The turnover zoomed to Rs. 2061.40 millions, up 52.02% for the September 2026 quarter as against Rs. 1356.00 millions during the year-ago period.Net profit for the quarter ended September 2026 increased significantly by 71.70% to Rs. 501.20 millions from Rs. 291.90 millions.OP of the company witnessed a marginal growth to 835.20 millions from 539.40 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202609	202509	% Var	202609	202509	% Var	202603	202503	% Var
Sales	2061.40	1356.00	52.02	3951.80	2290.60	72.52	5970.30	4774.10	25.06
Other Income	145.70	120.00	21.42	241.30	250.20	-3.56	381.40	696.70	-45.26
PBIDT	835.20	539.40	54.84	1490.90	868.00	71.76	1938.60	2058.00	-5.80
Interest	22.00	24.40	-9.84	47.30	46.70	1.28	100.40	58.70	71.04
PBDT	822.00	499.30	64.63	1487.50	753.80	97.33	2032.40	1541.90	31.81
Depreciation	154.60	136.10	13.59	309.50	266.70	16.05	551.10	488.60	12.79
PBT	667.40	363.20	83.76	1178.00	487.10	141.84	1481.30	1053.30	40.63
TAX	166.20	71.30	133.10	27.60	8.10	240.74	151.60	374.40	-59.51
Deferred Tax	9.50	0.90	955.56	-266.90	45.10	-691.80	76.60	-96.40	-179.46
PAT	501.20	291.90	71.70	1150.40	479.00	140.17	1329.70	678.90	95.86
Equity	195.60	97.80	100.00	195.60	97.80	100.00	195.60	97.80	100.00
PBIDTM(%)	40.52	39.78	1.85	37.73	37.89	-0.44	32.47	43.11	-24.68